Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
Tait D. Shanafelt(Mayo Clinic), Martin S. Tallman(Memorial Sloan Kettering Cancer Center), Susan O’Brien(University of California, Irvine), Steven Coutré(Georgetown University), Amanda F. Cashen(Washington University in St. Louis), Cong C. Zhang(Dana-Farber Cancer Institute), Harry P. Erba(Michigan Center for Translational Pathology), Richard F. Little(Dana-Farber Cancer Institute), Paul M. Barr(University of Rochester Medical Center), Michael P. Mullane(Dana-Farber Cancer Institute), Richard M. Stone(Dana-Farber Cancer Institute), Jacqueline C. Barrientos(Mount Sinai Medical Center), Avina K. Singh(Dana-Farber Cancer Institute), Esteban Braggio(Dana-Farber Cancer Institute), Anthony R. Mato(Memorial Sloan Kettering Cancer Center), Mark R. Litzow(Mayo Clinic in Arizona), Xin V. Wang(Dana-Farber Cancer Institute), Curtis A. Hanson(Toyota Motor Corporation (Switzerland)), Diane F. Jelinek(Mayo Clinic in Arizona), José F. Leis(Mayo Clinic), Neil E. Kay(Mayo Clinic)
Cited by 735
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3k